Doug Warner
Tyra Biosciences, Inc
3
0
0
N/A
0
3
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Rahul Aggarwal, MD
University of California, San Francisco
Shared therapeutic areas:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
James L Gulley, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Jason Wu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Shared therapeutic areas:
Mike Royal, MD
Sorrento Therapeutics, Inc.
Shared therapeutic areas:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
All 3 trials loaded